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a b s t r a c t
The assessment of metabolic function in cells isolated from human blood for treatment and diagnosis of
disease is a new and important area of translational research. It is now becoming clear that a broad range
of pathologies which present clinically with symptoms predominantly in one organ, such as the brain or
kidney, also modulate mitochondrial energetics in platelets and leukocytes allowing these cells to serve
as “the canary in the coal mine” for bioenergetic dysfunction. This opens up the possibility that
circulating platelets and leukocytes can sense metabolic stress in patients and serve as biomarkers of
mitochondrial dysfunction in human pathologies such as diabetes, neurodegeneration and cardiovascular
disease. In this overview we will describe how the utilization of glycolysis and oxidative phosphorylation
differs in platelets and leukocytes and discuss how they can be used in patient populations. Since it is
clear that the metabolic programs between leukocytes and platelets are fundamentally distinct the
measurement of mitochondrial function in distinct cell populations is necessary for translational
research.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
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Introduction
Circulating leukocytes and platelets are programmed for distinct
roles in normal physiology which include mediating the inﬂamma-
tory process, thrombosis, clearance of foreign bodies and sensing and
responding to systemic biological signals in the circulation. The
dynamic functions of peripheral blood leukocytes and platelets
require an integrated metabolic machinery to meet energetic demand
during normal physiology which is likely to involve both glycolysis
and mitochondrial oxidative phosphorylation. The role of both these
important ATP generating pathways in supporting the biological
function of platelets and leukocytes has been recognized but these
ﬁndings have not been integrated into an overall understanding of
these cell types in human subjects. This review analyzes the simila-
rities and differences in the glycolytic and oxidative metabolic proﬁles
in leukocytes and platelets from human subjects and discusses the
implications of these ﬁndings for the utilization of these cell types for
translational research.
Biological functions and metabolic programs of platelets and
leukocytes
The myeloid lineage supports the greatest variety of differentiated
circulating cells which include erythrocytes, platelets, neutrophils,
and monocytes. Monocytes are phagocytic cells with a uni-lobular
nucleus that have an important role in the innate immune system
[1–3]. Once secreted from the bone marrow into the blood, these cells
survey the body for sites of inﬂammation. On encountering inﬂam-
matory stress signals the monocytes must rapidly activate and
migrate to areas of injury where they can differentiate into the pro-
inﬂammatory (M1) or anti-inﬂammatory (M2) phenotype [3]. In the
M1 state the activated monocyte–macrophage cell undergoes a
metabolic switch from oxidative phosphorylation to glycolysis [4].
This change is important to provide substrates for biosynthetic
programs, maintain mitochondrial membrane potential and also
provide ATP to the cell [5]. Inhibition of oxidative phosphorylation
also increases reactive oxygen species (ROS) production which exerts
bactericidal activities [5]. During the resolution of inﬂammation, the
macrophages transform into the alternatively activated M2 pheno-
type and a more oxidative phosphorylation phenotype [6]. Thus the
metabolic programs of monocyte/macrophage populations are highly
plastic and adapt to facilitate the changing function of these cells in
the inﬂammatory process. Whether early changes in metabolic
phenotype associated with exposure to pro-inﬂammatory conditions
can be detected in the pre-differentiated monocyte in the circulation
is not clear. Typically, differentiation of the M1/M2 macrophages
occurs at the site of inﬂammation not in the circulation. From the
translational perspective the pre-differentiated monocyte is the
dominant form in the circulation. Monocytes are then a potentially
good sensor of metabolic stressors such as hyperlipidemia or hyper-
glycemia in the circulation of patients.
Lymphocytes are derived from the lymphoid lineage and are
uni-nucleated cells that play an important role in adaptive
immunity [7]. This heterogeneous population of cells is normally
in a quiescent state and primarily uses mitochondria to meet their
energetic demands [8]. Activation of lymphocytes is associated
with a switch to a metabolic phenotype with an increase in both
glycolytic function and mitochondrial oxygen consumption [9].
This is essential for their diverse immunological functions, which
includes clonal expansion and the production of cytokines and
antibodies [10–13]. From a translational perspective, the abun-
dance, heterogeneity, and reactivity of these cells make them ideal
for investigating the relationship of bioenergetics with the disease
processes associated with inﬂammation.
Neutrophils serve an essential function in the innate immune
system and are the ﬁrst line of defense during bacterial infection.
Neutrophils eliminate and destroy microorganisms by phagocytosis,
generation of ROS, the extrusion of genomic DNA as Neutrophil
Extracellular Traps (NETs), and by the release of cytotoxic granules
[14,15]. Neutrophils have very few mitochondria which do not play
a role in energy metabolism, but maintain their mitochondrial
membrane potential for apoptotic signaling [16–18]. The energy
required for neutrophil chemotaxis and activity is derived from
glycolysis [19]. The translational applications of the oxidative burst
in neutrophils have been well studied, but less is known regarding
the regulatory role of glycolysis under normal and pathological
conditions in these cells [20].
Platelets are cytoplasmic fragments that are released by mega-
karyocytes in the bone marrow and stored in the spleen. These
anuclear cells play an important role in hemostasis and are essential
for thrombus formation at sites of injury. With a lifetime of 5–7 days
in the circulation and no nucleus their metabolic program must be
stable over this time period and be available for the energy requiring
processes engaged when they are activated. At a basal state both
oxidative phosphorylation and glycolysis play a role in energy
production in platelets [21,22]. Platelet aggregation results in an
increase in glycolytic metabolism but it has been shown that a robust
oxidative phosphorylation system is required to enable optimal levels
of platelet functionality [23]. Platelets have been used widely in
translational research in a broad range of pathological conditions
including neurological disorders and diabetes [24]. In the next section
wewill demonstrate how the basal cellular bioenergetics are different
between these cell types and the implications these ﬁndings have for
translational research which use these cells as sensors of pathological
changes in mitochondrial dysfunction.
Leukocytes and platelets as systemic biomarkers of metabolic
stress
Many chronic pathological conditions such as metabolic syn-
drome, cancer and atherosclerosis are associated with an inﬂamma-
tory response with the release of proinﬂammatory mediators
particularly the cytokines. Leukocytes and platelets respond to these
pro-inﬂammatory mediators in the systemic circulation through an
activation process which changes the cellular phenotype as discussed
in the previous section. Several investigators have tested the concept
that leukocytes and platelets can act as biomarkers of mitochondrial
dysfunction associated with several diseases including diabetes,
neurodegenerative diseases, atherosclerosis and cancer [24–28]. For
example, patients with septic shock demonstrated a strong associa-
tion between decreased mitochondrial function, speciﬁcally loss of
ATP synthase activity, in peripheral blood mononuclear cells and
increased mortality [25]. It has also been shown that platelets from
patients with type 2 diabetes have lower mitochondrial membrane
potential and higher ATP content compared to controls [29]. A study
of mononuclear cells in type 2 diabetes showed that the mitochon-
drial mass was decreased and that the mitochondria were hyperpo-
larized [30]. Mitochondrial complex I activity was found to be
decreased in aged platelets [31] and those obtained from patients
with Alzheimer0s disease had higher mitochondrial membrane
potential than controls [32]. Furthermore, platelets derived from
normal individuals with a maternal history of Alzheimer0s had lower
cytochrome c oxidase activity [33]. It has been reported that
leukocytes from patients with leukemia have higher numbers of
circular dimer mitochondrial DNA compared to healthy controls,
suggesting that leukocyte mitochondrial function is also important
in cancer [34]. Mitochondria isolated from mononuclear cells in
patients with ﬁbromyalgia exhibited lower membrane potential and
levels of coenzyme Q10 but increased superoxide production [35].
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New approaches to measuring cellular bioenergetics
in leukocytes and platelets
Development of sensitive assays using an extracellular ﬂux
analyzer (XF) has advanced the translational application of bioe-
nergetics by making it possible to determine mitochondrial func-
tion in leukocytes and platelets isolated from peripheral blood
[22,36]. The XF analyzer measures oxygen consumption rate which
can be ascribed to mitochondrial respiration as well as the change
in pH which can be related to glycolysis [37–39]. Assays using
inhibitors of mitochondrial respiratory complexes and glycolysis
have developed sensitive protocols for the determination of
cellular bioenergetics in leukocytes and platelets [22,24,27].
Cellular mitochondrial physiology and glycolysis in platelets
and leukocytes
In a recent study we characterized the bioenergetic proﬁles in
human platelets, monocytes, leukocytes and neutrophils to deter-
mine how they selectively utilize glycolysis and oxidative
phosphorylation [22]. Here we will use data obtained from the
Fig. 1. Distinct mitochondrial metabolism in leukocytes and platelets. Monocytes, lymphocytes and platelets were isolated from blood collected from healthy donors as
described in [22]. The cells were seeded on a seahorse XF96 plate to assess bioenergetic function with a seahorse extracellular ﬂux analyzer. Basal oxygen consumption was
determined, followed by sequential injections of oligomycin, FCCP and antimycin A. The OCR was normalized to total protein based on number of cells plated per well.
(A) Indices of bioenergetics were determined in monocytes, lymphocytes and platelets from individual donors. n¼9–10. (B) Mitochondrial respiratory chain complexes and
TCA cycle protein expression in each cell type were determined by western blotting for cytochrome c oxidase subunit I and Reiske iron–sulfur protein and citrate synthase.
Isolated cells were solubilized in RIPA buffer and 50 mg of protein was resolved in SDS PAGE gels followed by western blotting. Data presented as mean77SEM n¼3
independent donors. *po0.05 and **po0.005.
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measurement of oxygen consumption and extracellular acidiﬁca-
tion after the sequential addition of mitochondrial inhibitors using
the methods described previously [22]. In Fig. 1A we show the
relative proportion of maximal mitochondrial oxygen consump-
tion dedicated to the major bioenergetic functions in monocytes,
lymphocytes, and platelets. Platelets dedicate over 50% of their
mitochondrial function to ATP synthesis which is approximately
double that used by monocytes or lymphocytes. The difference
between maximal oxygen consumption induced by uncoupling
and the basal respiration is termed the reserve or spare respiratory
capacity and can potentially be used by the cell for responses to
oxidative stress, additional work or movement of ions into the
mitochondria [37,40]. Reserve capacity is greatest in the mono-
cytes and lymphocytes while the platelet reserve capacity is only
approximately 20% of maximal mitochondrial function. The differ-
ences in the mitochondrial oxygen utilization by these cell types
indicate that they differ in the metabolic programs governing
energy generation. We surmised that these differences would be
reﬂected in the mitochondrial protein composition between each
cell type. As shown in Fig. 1B where the mitochondrial proteins
were quantiﬁed by western blot the citrate synthase levels
normalized to total cell protein were similar between platelets,
lymphocytes and monocytes. In contrast, Complex IV subunit I
protein, the catalytic portion of cytochrome c oxidase, is present at
higher levels in monocytes than in lymphocytes, whereas the
Reiske iron sulfur protein of complex III is found at higher levels in
lymphocytes. Both Complex III and IV proteins are low in platelets.
These data show that there are indeed differences in mitochon-
drial electron transport chain proteins in these cells which will
impact on the regulation and function of mitochondrial metabo-
lism. With respect to using these cell types as biomarkers of
bioenergetic function these ﬁndings have important implications.
For example, detection of a pathology associated with decreased
cytochrome c oxidase will be most readily detected in platelets
which have the lowest levels of this enzyme and will be less
evident in monocytes. It also follows that measurement of mito-
chondrial function in a crude preparation of peripheral blood
mononuclear cells (PBMCs) will be a weighted average of the
bioenergetic activity of diverse cell types which cannot then serve
as an optimal sensor of bioenergetic health [41].
Differential glycolytic and oxidative metabolism in leukocytes
and platelets
To gain further insight into the relative utilization of glycolysis
and oxidative phosphorylation in circulating platelets and mono-
cytes we show the plot of OCR vs ECAR under basal conditions and
with inhibition of mitochondrial ATP synthesis by oligomycin
(Fig. 2A). Platelets have the highest basal OCR and show the
largest increase on inhibition of mitochondrial ATP synthase.
Monocytes have a slightly lower basal OCR compared to platelets
and a more modest increase in glycolysis on addition of oligomy-
cin. Lymphocytes are predominantly utilizing oxidative phosphor-
ylation under basal conditions and have a limited capacity to
increase glycolytic ﬂux on addition of oligomycin. Neutrophils
have little or no dependence on oxidative phosphorylation and not
surprisingly glycolysis is not increased when the mitochondrial
ATP synthase is inhibited although it is highly induced on activa-
tion of the oxidative burst [22]. In Fig. 2B these data are
represented as the proportional difference in the OCR/ECAR ratio
for each cell type across the full spectrum of glycolytic and
mitochondrial metabolism. Interestingly, both platelets and mono-
cytes exhibit a high degree of aerobic glycolysis whereas lympho-
cytes are almost entirely oxidative and neutrophils entirely
glycolytic. Platelets appear to be the most metabolically active
circulating “cells” under basal conditions which may be related to
their relatively small size and high surface area associated with the
extensive open canicular system of the cell. It is critical for
platelets to maintain their calcium and other ion balance during
circulation to prevent inadvertent activation, and many of these
channels require ATP to function. The neutrophils are an interest-
ing contrast as their mitochondria perform other roles, such as
redox signaling and controlling apoptosis, which are more impor-
tant for the function of these cells [42].
Future outlook
These data clearly indicate how the metabolic programs are
distinct in the circulating leukocytes and platelets. In translational
research the platelets and monocytes can then act as differential
sensors of the metabolic and inﬂammatory stresses associated
with cardiovascular disease, neurodegeneration, diabetes or other
chronic pathologies. Lymphocytes in the circulation represent
mixed populations due to clonal expansion and as such their
bioenergetics may be an index of the status of inﬂammation or
infection. Neutrophils are predominantly glycolytic and changes in
oxidative burst capacity rather than mitochondrial function will be
more informative. Changes in cellular bioenergetics in these cell
types can then sense both changes in their biological function in
response to an underlying pathological condition and their
response to chronic metabolic stress. In summary, we have shown
that using an integrated approach, the glycolytic metabolism and
oxidative phosphorylation can be combined to generate a unique
Fig. 2. Distinct glycolytic metabolism in leukocytes and platelets. Oxygen con-
sumption rate and extracellular acidiﬁcation rate (ECAR) were measured in isolated
monocytes, lymphocytes, platelets and neutrophils from healthy donors. (A) The
basal and oligomycin sensitive mitochondrial bioenergetics (OCR) and glycolytic
(ECAR) rates are plotted for each cell type. (B) The basal OCR/ECAR ratio is shown
plotted at the approximate position showing the relative use of glycolysis (100% on
the left) and oxidative phosphorylation (100% on the right). Data presented as
mean7SEM n¼9–10 independent healthy donors.
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cellular bioenergetic proﬁle for each cell type which extends the
analysis of metabolic dysfunction in translational research.
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